Ananda Pharma PLC - TGA Receives Ananda’s Clinical Trial Notification

Ananda Pharma plc (AQSE: ANA, OTCQB: ANANF), a UK-based biopharmaceutical company developing regulatory approved, cannabinoid medicines to treat complex, chronic conditions, is pleased to announce that its Phase I clinical trial, "A Phase 1, Open-Label, Multiple Dose Study to Assess the Pharmacokinetics, Safety, Tolerability, and Food Effect of MRX1 in Healthy Adults", has been acknowledged by the Therapeutic Goods Administration ("TGA") in Australia under the Clinical Trial Notification ("CTN") scheme.

MRX1 is Ananda's lead investigational cannabidiol (CBD) drug formulation, in development for complex chronic inflammatory pain conditions. It is derived from high-purity, pharmaceutical-grade CBD, manufactured to stringent quality control standards to ensure consistency and stability.

Highlights:

Ananda's CEO, Melissa Sturgess, commented: "We are pleased to receive acknowledgement of our clinical trial under the TGA's CTN scheme, which is an important milestone in advancing our MRX1 development program. The data from this trial will be key for regulatory filings in the US, UK and Europe."

"Australia is an attractive location for clinical research due to its streamlined regulatory process and high-quality clinical trial infrastructure. This strategy is now paying off and we look forward to initiating the study and advancing our efforts to bring MRX1 to patients in need."